A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results

A. T. Meadows, R. D.T. Jenkin, J. Anderson, R. Chilcote, P. Coccia, P. Exelby, J. Kushner, S. Leikin, S. Siegel, J. F. Wilson, D. Hammond

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

A pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed. From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.

Original languageEnglish (US)
Pages (from-to)15-24
Number of pages10
JournalMedical and Pediatric Oncology
Volume8
Issue number1
DOIs
StatePublished - 1980

Keywords

  • multidisciplinary therapy (COMP)
  • non‐Hodgkin's lymphoma
  • staging
  • survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results'. Together they form a unique fingerprint.

  • Cite this

    Meadows, A. T., Jenkin, R. D. T., Anderson, J., Chilcote, R., Coccia, P., Exelby, P., Kushner, J., Leikin, S., Siegel, S., Wilson, J. F., & Hammond, D. (1980). A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results. Medical and Pediatric Oncology, 8(1), 15-24. https://doi.org/10.1002/mpo.2950080104